Browse Category

Company News News 3 December 2025 - 4 December 2025

Unilever PLC Stock in December 2025: Magnum Spin‑Off, Graze Sale, Share Cancellation and What Analysts Expect Next

Unilever PLC Stock in December 2025: Magnum Spin‑Off, Graze Sale, Share Cancellation and What Analysts Expect Next

Meta description:Unilever PLC stock (LSE: ULVR, NYSE: UL) enters December 2025 amid the Magnum Ice Cream spin‑off, the sale of Graze, a fresh share cancellation and renewed scrutiny of its sustainability claims. Here’s how these moves, plus analyst forecasts and
South32 (ASX: S32) Stock on 4 December 2025: Share Price, Cerro Matoso Exit, New ESG Director and 2026–2028 Outlook

South32 (ASX: S32) Stock on 4 December 2025: Share Price, Cerro Matoso Exit, New ESG Director and 2026–2028 Outlook

South32 Limited (ASX/LSE/JSE: S32; ADR: SOUHY) enters December 2025 amid a burst of corporate news: completion of a major nickel divestment, a new director with heavyweight ESG credentials, fresh buy‑back activity and a portfolio increasingly geared to energy‑transition metals. Here’s
4 December 2025
Newmont Stock (NEM) After December 3, 2025: Record Free Cash Flow, Job Cuts and Insider Selling – Is There Still Upside?

Newmont Stock (NEM) After December 3, 2025: Record Free Cash Flow, Job Cuts and Insider Selling – Is There Still Upside?

Newmont Corporation (NYSE: NEM), the world’s largest gold miner, has turned into one of 2025’s standout large-cap performers. As of the close on December 3, 2025, Newmont stock changed hands around $89–90 per share, giving the company a market capitalization
Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron

Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is ending 2025 in full “complex biotech” mode: the share price has rebounded, the dividend is now real, a flagship drug just got a powerful new label, a rare-disease medicine crushed a Phase 3 trial,
1 11 12 13 14 15 42
Go toTop